PAP
INDV icon

Persistent Asset Partners’s Indivior Pharmaceuticals INDV Stock Holding History

Persistent Asset Partners’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-587
Closed -$159K – 398
2025
Q4 		$159K Buy
+587
New +$17.9K 0.07% 239

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Persistent Asset Partners's INDV Position: Q2 2026 in Review

Persistent Asset Partners increased its Indivior Pharmaceuticals (INDV) stake by 38% in Q2 2026, buying an estimated $251K and bringing the position to 24,934 shares worth $1.02M. The position accounts for 0.31% of the portfolio, ranked #63.

Persistent Asset Partners first reported a position in INDV in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.41M in Q3 2025. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Persistent Asset Partners held 24,934 shares of Indivior Pharmaceuticals worth $1.02M as of Q2 2026.
  • Persistent Asset Partners bought 6,922 Indivior Pharmaceuticals shares in Q2 2026, an estimated $251K.
  • Indivior Pharmaceuticals made up 0.31% of Persistent Asset Partners's portfolio in Q2 2026, its #63 holding.
  • Persistent Asset Partners first reported a position in Indivior Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Persistent Asset Partners's Indivior Pharmaceuticals position peaked at $1.41M in Q3 2025.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.